NCT00612885已完成不适用
Post Marketing Surveillance to Assess the Safety and Efficacy of Mobic® (Meloxicam) Intramuscular Injection (7.5mg ~ 15mg, q.d.) up to 3 Days (in Case of Need for Prolonged Treatment, Switch to Mobic® Capsule Therapy Was Possible) in Korean Patients With Osteoarthritis and Rheumatoid Arthritis (KFDA Regulatory Requirement PMS)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 425
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
The main objective of this PMS study was to monitor and assess the safety of Mobic® intramuscular injection (7.5mg ~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to Mobic® capsule therapy was possible) in Korean patients with osteoarthritis and rheumatoid arthritis.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Incidence of adverse events
时间窗: up tp 3 day
Efficacy assessment by the treating physician
时间窗: up to 3 day
Combined efficacy, safety and tolerability assessment by the treating physician
时间窗: up tp 3 day
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential HypertensionHypertensionNCT02245464Boehringer Ingelheim13,066
招募中
不适用
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea PatientsHyperphosphatemiaNCT06186934Kyowa Kirin Korea Co., Ltd.600
招募中
不适用
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean PatientsFGF23-related Hypophosphataemic Rickets and OsteomalaciaNCT06202027Kyowa Kirin Korea Co., Ltd.100
已完成
不适用
A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox CapsuleSchizophreniaBipolar DisorderNCT01053429Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3,391
已完成
不适用
Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing SurveillanceHyperlipidemiaNCT02730390Otsuka Pharmaceutical, Inc., Philippines3,087